In 2020, EFA continued its partnership in 3TR, the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project. The project aims to improve our knowledge on how patients with allergic and inflammatory diseases, including asthma and COPD, respond to treatments, and thus, how to enhance personalised therapies.
EFA helped to coordinate a Respiratory Patient Working Group (RPWG) to ensure that patients are at the centre of the project activities. The RPWG is composed of 24 adult asthma and COPD patients from 7 European countries. Since October 2020, EFA has recruited a group of young asthma patients, aged between 15 and 27 years old from 4 European countries, to bring the youth perspective to the 3TR project, increasing the number of RPWG members to 31. The involvement of both young and adult groups was key to supporting researchers in identifying relevant patient-centred biomarkers and defining responses to biological therapy for severe asthma. These same activities will be carried out in 2021 for COPD patients.
